Harbour BioMed inks collaboration with AstraZeneca to discover and develop next-generation therapeutic antibodies: Shanghai & Rotterdam, The Netherlands Tuesday, March 25, 2025, 1 ...

The Swiss biopharmaceutical company Light Chain Bioscience has developed a novel and unique class of human, bispecific antibodies dubbed κλ bodies, so-called because they combine a κ light ...

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

The following is a summary of “Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis,” published in the March 2025 issue of Neurology Neuroimmunology & ...

Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...

Paradox is focused on the development of treatment for immunoglobulin light chain amyloidosis (AL amyloidosis ... platform and bringing much-needed antibody therapies to market.” ...

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused ...

"Our study sheds new light on the relationship between the various structures of antibodies and their properties after protein translation," said FSU faculty researcher Fanny C. Liu, who was the ...

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, �lanc� aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle ...